

Alexandre Prat

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/568576/alexandre-prat-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

178
papers

14,124
citations

62
h-index

116
g-index

196
ext. papers

17,581
ext. citations

11.3
avg, IF

6.57
L-index

#	Paper	IF	Citations
178	DICAM promotes T17 lymphocyte trafficking across the blood-brain barrier during autoimmune neuroinflammation.. <i>Science Translational Medicine</i> , 2022 , 14, eabj0473	17.5	3
177	Administration of Maresin-1 ameliorates the physiopathology of experimental autoimmune encephalomyelitis.. <i>Journal of Neuroinflammation</i> , 2022 , 19, 27	10.1	2
176	Productivity loss among people with early multiple sclerosis: A Canadian study.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069070	5	1
175	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. <i>Science Advances</i> , 2021 , 7, eabj5629	14.3	8
174	Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites. <i>Acta Neuropathologica</i> , 2021 , 141, 725-754	14.3	5
173	Identification of SARS-CoV-2-specific immune alterations in acutely ill patients. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	6
172	Barcoded viral tracing of single-cell interactions in central nervous system inflammation. <i>Science</i> , 2021 , 372,	33.3	29
171	Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases. <i>Nature Reviews Neurology</i> , 2021 , 17, 433-447	15	4
170	Frailty in ageing persons with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 613-620	5	9
169	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 755-766	5	3
168	IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5/IL-1R8. <i>Theranostics</i> , 2021 , 11, 1-13	12.1	7
167	The IL-27/IL-27R axis is altered in CD4 and CD8 T lymphocytes from multiple sclerosis patients. <i>Clinical and Translational Immunology</i> , 2021 , 10, e1262	6.8	0
166	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1838-1851	5	2
165	Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia. <i>Nature Neuroscience</i> , 2021 , 24, 489-503	25.5	21
164	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103012	4	3
163	CCR6 Expression on B Cells Is Not Required for Clinical or Pathological Presentation of MOG Protein-Induced Experimental Autoimmune Encephalomyelitis despite an Altered Germinal Center Response. <i>Journal of Immunology</i> , 2021 , 207, 1513-1521	5.3	0
162	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021 , 35, 1217-1232	6.7	1

161	Gut-licensed IFN γ NK cells drive LAMP1 ⁺ TRAIL ⁺ anti-inflammatory astrocytes. <i>Nature</i> , 2021 , 590, 473-479	50.4	63
160	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020 , 143, 1400-1413	11.2	13
159	From BalB concentric sclerosis to multiple sclerosis: a series of 6 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 42, 102078	4	4
158	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , 2020 , 19, 307-316	24.1	77
157	A roadmap to precision medicine for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 522-532	5	12
156	Successful Management of Natalizumab-Associated Primary Central Nervous System Lymphoma through Autologous Stem Cell Transplant. <i>Current Oncology</i> , 2020 , 28, 203-208	2.8	1
155	QUAKING Regulates Microexon Alternative Splicing of the Rho GTPase Pathway and Controls Microglia Homeostasis. <i>Cell Reports</i> , 2020 , 33, 108560	10.6	3
154	MAFG-driven astrocytes promote CNS inflammation. <i>Nature</i> , 2020 , 578, 593-599	50.4	125
153	Glial Cells as Regulators of Neuroimmune Interactions in the Central Nervous System. <i>Journal of Immunology</i> , 2020 , 204, 251-255	5.3	14
152	Overcoming the Brain Barriers: From Immune Cells to Nanoparticles. <i>Trends in Pharmacological Sciences</i> , 2020 , 41, 42-54	13.2	15
151	Interpericyte tunnelling nanotubes regulate neurovascular coupling. <i>Nature</i> , 2020 , 585, 91-95	50.4	73
150	Interleukin-26, preferentially produced by T17 lymphocytes, regulates CNS barrier function. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	7
149	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020 , 77, 1398-1407	17.2	8
148	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020 , 143, 2742-2756	11.2	8
147	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 79-90	5	27
146	RNA-binding protein altered expression and mislocalization in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	7
145	Assessing the risk of multiple sclerosis disease-modifying therapies. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 695-706	4.3	3
144	Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. <i>Nature Neuroscience</i> , 2019 , 22, 729-740	25.5	166

143	Inflammation-induced endothelial to mesenchymal transition promotes brain endothelial cell dysfunction and occurs during multiple sclerosis pathophysiology. <i>Cell Death and Disease</i> , 2019 , 10, 45	9.8	22
142	Sex-dependent factors encoded in the immune compartment dictate relapsing or progressive phenotype in demyelinating disease. <i>JCI Insight</i> , 2019 , 4,	9.9	3
141	MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis. <i>Brain</i> , 2019 , 142, 2979-2995	11.2	32
140	Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	27
139	Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry. <i>ELife</i> , 2019 , 8,	8.9	33
138	Author response: Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry 2019 ,		2
137	IVIVC Assessment of Two Mouse Brain Endothelial Cell Models for Drug Screening. <i>Pharmaceutics</i> , 2019 , 11,	6.4	9
136	Isolation of endothelial cells, pericytes and astrocytes from mouse brain. <i>PLoS ONE</i> , 2019 , 14, e0226302	3.7	9
135	Metabolic Control of Astrocyte Pathogenic Activity via cPLA2-MAVS. <i>Cell</i> , 2019 , 179, 1483-1498.e22	56.2	59
134	Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. <i>Cell</i> , 2019 , 176, 610-624.e18	57.1	33
133	Environmental Control of Astrocyte Pathogenic Activities in CNS Inflammation. <i>Cell</i> , 2019 , 176, 581-596.e18	56.8	74
132	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 28, 235-243	4	22
131	CD70 defines a subset of proinflammatory and CNS-pathogenic T1/T17 lymphocytes and is overexpressed in multiple sclerosis. <i>Cellular and Molecular Immunology</i> , 2019 , 16, 652-665	15.4	24
130	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 175-187	27.4	172
129	EGFL7 reduces CNS inflammation in mouse. <i>Nature Communications</i> , 2018 , 9, 819	17.4	21
128	IL-1 β enables CNS access to CCR2 monocytes and the generation of pathogenic cells through GM-CSF released by CNS endothelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E1194-E1203	11.5	49
127	Notch signaling is impaired during inflammation in a Lunatic Fringe-dependent manner. <i>Brain, Behavior, and Immunity</i> , 2018 , 69, 48-56	16.6	8
126	Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption. <i>Journal of Neuroimmunology</i> , 2018 , 319, 9-12	3.5	10

125	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 642-652	5	18
124	Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1617-1626	5	21
123	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018 , 75, 1407-1415	17.2	13
122	Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis. <i>Journal of Neuroinflammation</i> , 2018 , 15, 114	10.1	27
121	Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. <i>Canadian Journal of Neurological Sciences</i> , 2018 , 45, 489-503	1	25
120	Humanized mouse model of Rasmussen's encephalitis supports the immune-mediated hypothesis. <i>Journal of Clinical Investigation</i> , 2018 , 128, 2000-2009	15.9	14
119	Neuronal microRNA regulation in Experimental Autoimmune Encephalomyelitis. <i>Scientific Reports</i> , 2018 , 8, 13437	4.9	18
118	Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 72-81	5	41
117	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 266-276	5	22
116	Dual role of ALCAM in neuroinflammation and blood-brain barrier homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E524-E533	11.5	53
115	Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses. <i>Journal of Immunology</i> , 2017 , 198, 3245-3254	5.3	22
114	Laquinimod enhances central nervous system barrier functions. <i>Neurobiology of Disease</i> , 2017 , 102, 60-69.5	13	13
113	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , 2017 , 16, 271-281	24.1	101
112	Multiple sclerosis-associated uveitis. <i>Expert Review of Ophthalmology</i> , 2017 , 12, 57-67	1.5	3
111	An updated histological classification system for multiple sclerosis lesions. <i>Acta Neuropathologica</i> , 2017 , 133, 13-24	14.3	253
110	Targeting the GM-CSF receptor for the treatment of CNS autoimmunity. <i>Journal of Autoimmunity</i> , 2017 , 84, 1-11	15.5	35
109	USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation. <i>Nature Immunology</i> , 2017 , 18, 54-63	19.1	51
108	ALCAM (CD166) is involved in extravasation of monocytes rather than T cells across the blood-brain barrier. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017 , 37, 2894-2909	7.3	39

107	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017 , 140, 2426-2443	11.2	62
106	Glial influences on BBB functions and molecular players in immune cell trafficking. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016 , 1862, 472-82	6.9	81
105	IL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation. <i>Brain</i> , 2016 , 139, 1939-57	11.2	62
104	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016 , 80, 89-100	9.4	117
103	Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?. <i>Trends in Neurosciences</i> , 2016 , 39, 325-339	13.3	58
102	One more role for the gut: microbiota and blood brain barrier. <i>Annals of Translational Medicine</i> , 2016 , 4, 15	3.2	20
101	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016 , 139, 2395-405	11.2	172
100	Production of IL-27 in multiple sclerosis lesions by astrocytes and myeloid cells: Modulation of local immune responses. <i>Glia</i> , 2016 , 64, 553-69	9	38
99	EphrinB1 and EphrinB2 regulate T cell chemotaxis and migration in experimental autoimmune encephalomyelitis and multiple sclerosis. <i>Neurobiology of Disease</i> , 2016 , 91, 292-306	7.5	15
98	Comparative efficacy of first-line natalizumab vs IFN- β glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016 , 6, 102-115	1.7	21
97	Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. <i>Nature Medicine</i> , 2016 , 22, 586-97	50.5	629
96	Myeloid cell transmigration across the CNS vasculature triggers IL-1 β -driven neuroinflammation during autoimmune encephalomyelitis in mice. <i>Journal of Experimental Medicine</i> , 2016 , 213, 929-49	16.6	93
95	Glial regulation of the blood-brain barrier in health and disease. <i>Seminars in Immunopathology</i> , 2015 , 37, 577-90	12	32
94	Netrin 1 regulates blood-brain barrier function and neuroinflammation. <i>Brain</i> , 2015 , 138, 1598-612	11.2	103
93	Update on treatments in multiple sclerosis. <i>Presse Medicale</i> , 2015 , 44, e137-51	2.2	25
92	An optimized method to process mouse CNS to simultaneously analyze neural cells and leukocytes by flow cytometry. <i>Journal of Neuroscience Methods</i> , 2015 , 247, 23-31	3	34
91	Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. <i>Science Translational Medicine</i> , 2015 , 7, 310ra166	17.5	242
90	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015 , 138, 3287-98	11.2	107

89	Focal disturbances in the blood-brain barrier are associated with formation of neuroinflammatory lesions. <i>Neurobiology of Disease</i> , 2015 , 74, 14-24	7.5	87
88	JAML mediates monocyte and CD8 T cell migration across the brain endothelium. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 1032-7	5.3	26
87	Melanoma cell adhesion molecule-positive CD8 T lymphocytes mediate central nervous system inflammation. <i>Annals of Neurology</i> , 2015 , 78, 39-53	9.4	43
86	B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. <i>Frontiers in Immunology</i> , 2015 , 6, 636	8.4	82
85	Roles of CD4 and CD8 T Lymphocytes in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis 2015 , 39-52		0
84	Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation. <i>Immunity</i> , 2015 , 43, 1160-73	32.3	117
83	The blood-brain barrier. <i>Cold Spring Harbor Perspectives in Biology</i> , 2015 , 7, a020412	10.2	1245
82	Blood-Brain Barrier Disruption in Multiple Sclerosis 2015 , 1-22		
81	Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2015 , 6, 626	8.4	57
80	Meningeal Tertiary Lymphoid Tissues and Multiple Sclerosis: A Gathering Place for Diverse Types of Immune Cells during CNS Autoimmunity. <i>Frontiers in Immunology</i> , 2015 , 6, 657	8.4	52
79	Ephrin B1 and B2 are essential for the pathogenicity and migration capacity of TH17 cells in EAE and MS. <i>Journal of Neuroimmunology</i> , 2014 , 275, 140	3.5	2
78	Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases. <i>Journal of Immunology</i> , 2014 , 193, 2438-54	5.3	140
77	Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. <i>Nature Medicine</i> , 2014 , 20, 1147-56	50.5	267
76	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon β <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1783-7	5	25
75	A novel microRNA-132-sirtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis [corrected]. <i>PLoS ONE</i> , 2014 , 9, e105421	3.7	65
74	Therapeutic decisions in multiple sclerosis: moving beyond efficacy. <i>JAMA Neurology</i> , 2013 , 70, 1315-24	17.2	67
73	MicroRNAs regulate human brain endothelial cell-barrier function in inflammation: implications for multiple sclerosis. <i>Journal of Neuroscience</i> , 2013 , 33, 6857-63	6.6	107
72	Glial influence on the blood brain barrier. <i>Glia</i> , 2013 , 61, 1939-58	9	318

71	How do immune cells support and shape the brain in health, disease, and aging?. <i>Journal of Neuroscience</i> , 2013 , 33, 17587-96	6.6	198
70	Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. <i>Annals of Neurology</i> , 2013 , 73, 341-54	9.4	105
69	Retinoic acid induces blood-brain barrier development. <i>Journal of Neuroscience</i> , 2013 , 33, 1660-71	6.6	139
68	Immunologic privilege in the central nervous system and the blood-brain barrier. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013 , 33, 13-21	7.3	188
67	Extracellular matrix metalloproteinase inducer shows active perivascular cuffs in multiple sclerosis. <i>Brain</i> , 2013 , 136, 1760-77	11.2	33
66	Cytotoxic NKG2C+ CD4 T cells target oligodendrocytes in multiple sclerosis. <i>Journal of Immunology</i> , 2013 , 190, 2510-8	5.3	60
65	Treatment optimization in MS: Canadian MS Working Group updated recommendations. <i>Canadian Journal of Neurological Sciences</i> , 2013 , 40, 307-23	1	159
64	Inflammation at the BloodBrain Barrier in Multiple Sclerosis. <i>Topics in Medicinal Chemistry</i> , 2013 , 117-142.4		
63	Endo-MitoEGFP mice: a novel transgenic mouse with fluorescently marked mitochondria in microvascular endothelial cells. <i>PLoS ONE</i> , 2013 , 8, e74603	3.7	5
62	Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS. <i>PLoS ONE</i> , 2012 , 7, e40443	3.7	87
61	Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis. <i>Glia</i> , 2012 , 60, 1145-59	9	87
60	Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system. <i>Brain</i> , 2012 , 135, 2906-24	11.2	97
59	Peroxisome proliferator-activated receptor (PPAR) and -regulate IFN and IL-17A production by human T cells in a sex-specific way. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 9505-10	11.5	125
58	Disruption of central nervous system barriers in multiple sclerosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011 , 1812, 252-64	6.9	212
57	Special issue on molecular basis of multiple sclerosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011 , 1812, 131	6.9	2
56	B cell-derived IL-15 enhances CD8 T cell cytotoxicity and is increased in multiple sclerosis patients. <i>Journal of Immunology</i> , 2011 , 187, 4119-28	5.3	46
55	How do immune cells overcome the blood-brain barrier in multiple sclerosis?. <i>FEBS Letters</i> , 2011 , 585, 3770-80	3.8	232
54	The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. <i>Science</i> , 2011 , 334, 1727-31	33.3	513

53	Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2011 , 8, 155	10.1	40
52	Role of Ninjurin-1 in the migration of myeloid cells to central nervous system inflammatory lesions. <i>Annals of Neurology</i> , 2011 , 70, 751-63	9.4	99
51	Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α 4 integrin. <i>Brain</i> , 2011 , 134, 3560-77	11.2	92
50	Isolation of human brain endothelial cells and characterization of lipid raft-associated proteins by mass spectroscopy. <i>Methods in Molecular Biology</i> , 2011 , 686, 275-95	1.4	14
49	Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. <i>Annals of Neurology</i> , 2009 , 66, 390-402	9.4	390
48	Functions of lipid raft membrane microdomains at the blood-brain barrier. <i>Journal of Molecular Medicine</i> , 2009 , 87, 765-74	5.5	46
47	Blood-brain barrier promotes differentiation of human fetal neural precursor cells. <i>Stem Cells</i> , 2009 , 27, 838-46	5.8	28
46	Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. <i>Nature Medicine</i> , 2009 , 15, 788-93	50.5	93
45	Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. <i>Nature Immunology</i> , 2008 , 9, 137-45	19.1	309
44	The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. <i>Brain</i> , 2008 , 131, 785-99	11.2	141
43	Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis. <i>Journal of Biological Chemistry</i> , 2008 , 283, 27220-9	5.4	87
42	Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. <i>Journal of Immunology</i> , 2008 , 181, 5730-7	5.3	200
41	Death receptor expression and function at the human blood brain barrier. <i>Journal of the Neurological Sciences</i> , 2007 , 259, 53-60	3.2	32
40	Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. <i>Nature Medicine</i> , 2007 , 13, 1173-5	50.5	1178
39	Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems. <i>Pharmaceutical Research</i> , 2007 , 24, 1262-74	4.5	55
38	Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. <i>Journal of Neuroscience</i> , 2007 , 27, 9032-42	6.6	178
37	NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. <i>Journal of Neuroscience</i> , 2007 , 27, 1220-8	6.6	77
36	Th1 polarization of CD4+ T cells by Toll-like receptor 3-activated human microglia. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 848-59	3.1	27

35	Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. <i>Annals of Neurology</i> , 2006 , 60, 45-55	9.4	127
34	Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. <i>Archives of Neurology</i> , 2005 , 62, 795-800		27
33	Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1. <i>Journal of Autoimmunity</i> , 2005 , 24, 119-24	15.5	37
32	Pathogenesis of multiple sclerosis. <i>Current Opinion in Neurology</i> , 2005 , 18, 225-30	7.1	115
31	Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. <i>Archives of Neurology</i> , 2005 , 62, 563-8		76
30	Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. <i>Clinical Immunology</i> , 2004 , 111, 38-46	9	18
29	Regulation of cellular and molecular trafficking across human brain endothelial cells by Th1- and Th2-polarized lymphocytes. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004 , 63, 223-32	3.1	31
28	Regulation and functional effects of monocyte migration across human brain-derived endothelial cells. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003 , 62, 412-9	3.1	69
27	Human brain endothelial cells supply support for monocyte immunoregulatory functions. <i>Journal of Neuroimmunology</i> , 2003 , 135, 96-106	3.5	9
26	Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia. <i>Glia</i> , 2003 , 42, 36-45	9	31
25	Determinants of human B cell migration across brain endothelial cells. <i>Journal of Immunology</i> , 2003 , 170, 4497-505	5.3	155
24	Migration of multiple sclerosis lymphocytes through brain endothelium. <i>Archives of Neurology</i> , 2002 , 59, 391-7		99
23	NG2 immunoreactivity on human brain endothelial cells. <i>Acta Neuropathologica</i> , 2001 , 102, 313-20	14.3	18
22	Glial cell influence on the human blood-brain barrier. <i>Glia</i> , 2001 , 36, 145-55	9	254
21	T lymphocytes conditioned with Interferon beta induce membrane and soluble VCAM on human brain endothelial cells. <i>Journal of Neuroimmunology</i> , 2001 , 115, 161-7	3.5	32
20	Regulation of Th1 and Th2 lymphocyte migration by human adult brain endothelial cells. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001 , 60, 1127-36	3.1	68
19	Brain-immune connection: Immuno-regulatory properties of CNS-resident cells. <i>Glia</i> , 2000 , 29, 293-304	9	289
18	Heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: Relation to magnetic resonance imaging lesion volume. <i>Annals of Neurology</i> , 2000 , 47, 234-237	9.4	21

17	Antigen and superantigen presentation in the human CNS. <i>Journal of Neuroimmunology</i> , 2000 , 107, 118-23	3.3	7
16	Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2000 , 108, 201-6	3.5	63
15	B7 expression and antigen presentation by human brain endothelial cells: requirement for proinflammatory cytokines. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000 , 59, 129-36	3.1	47
14	Kinin B1 receptor expression and function on human brain endothelial cells. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000 , 59, 896-906	3.1	61
13	Brain-immune connection: Immuno-regulatory properties of CNS-resident cells 2000 , 29, 293		11
12	Interferon- β secretion by peripheral blood T-cell subsets in multiple sclerosis: Correlation with disease phase and interferon- β therapy. <i>Annals of Neurology</i> , 1999 , 45, 247-250	9.4	78
11	Lymphocyte migration and multiple sclerosis: relation with disease course and therapy. <i>Annals of Neurology</i> , 1999 , 46, 253-6	9.4	48
10	Interferon- β secretion by peripheral blood T-cell subsets in multiple sclerosis: Correlation with disease phase and interferon- β therapy 1999 , 45, 247		2
9	Characterization of the tachykinin receptors involved in spinal and supraspinal cardiovascular regulation. <i>Canadian Journal of Physiology and Pharmacology</i> , 1995 , 73, 892-902	2.4	26
8	Cardiovascular and behavioural effects of centrally administered neuropeptide K in the rat: receptor characterization. <i>British Journal of Pharmacology</i> , 1994 , 112, 250-6	8.6	13
7	Neuropeptide K potently stimulates the hydrolysis of phosphatidylinositol in the rat spinal cord. <i>Neuroscience Letters</i> , 1993 , 159, 95-8	3.3	2
6	Characterization of the cardiovascular and behavioral effects of centrally administered neuropeptide K in the conscious rat. <i>Regulatory Peptides</i> , 1993 , 46, 317-20		1
5	Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat. <i>British Journal of Pharmacology</i> , 1992 , 107, 750-5	8.6	38
4	Anaesthetic doses of pentobarbital antagonize phosphatidylinositol hydrolysis induced by substance P or carbachol in the spinal cord and cerebral cortex of the rat. <i>European Journal of Pharmacology</i> , 1992 , 227, 103-7		6
3	Oxidative Modifications of Parkin Underlie its Selective Neuroprotection in Adult Human Brain		2
2	Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry		1
1	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality		5